XXXX for treatment of @entity1443 @entity8956 in the cat.

@entity12757 @entity308 @entity4 @entity898 @entity468 @entity1443 @entity8956 @entity848
Acute @entity1443 intoxication in the cat was studied to characterize the antidotal profile of @entity898 . @entity8956 was associated with @entity848 , hyperventilation, @entity308 , and @entity4 . Abnormal laboratory findings were @entity12757 and elevated serum glutamic-pyruvic transaminase activity. In one trial, each of ten @entity468 was given a 325-mg tablet of @entity1443 , then another after 4 hours. Five of the @entity468 were given antidotal treatment with @entity898 (140 mg/kg, per os) at the time of the second dosing with @entity1443 and at 8-hour intervals thereafter for a total of three treatments. All treated @entity468 survived. Two of the untreated @entity468 died. In another trial, doubling each dose of @entity1443 (650 mg) proved fatal in all of four untreated cats. When antidotal therapy was initiated at the time of the second dosing with @entity1443 and repeated at 8- or 4-hour intervals for three treatments, two of four @entity468 in each treatment group survived. Although antidotal therapy was associated with a return of serum glutamic-pyruvic transaminase and @entity12757 values toward normal, only the methemoglobin value was a reliable prognostic indicator.
